Support MS Research

Sign Up to eNewsletter

Be the first to receive the latest news on MS Research.

What are Clinical Trials?

Clinical trials help to determine if a new drug, or other intervention such as surgery or physiotherapy, is safe and effective. They may be run by allied health professionals, doctors, researchers or the pharmaceutical industry. In all cases, trials must be approved by a human research and ethics committee (HREC) that reviews the trial protocol, the research evidence to support the trial and its potential risks and benefits.

 

Trial design

Trial protocols are carefully designed using techniques such as ‘blinding’, ‘randomisation’ and placebo controls to guard against bias and ensure that the results can be accurately interpreted.

Placebos are 'dummy' pills in which the active ingredient, the drug, is replaced by an inactive substance. The placebo looks identical to the drug being trialed, so that the patient and treating or assessing doctor are unaware or 'blinded' as to whether the patient is receiving drug or placebo. For surgical procedures a sham procedure is sometimes performed in which, for example an incision is made, but the full procedure is not performed. 

Placebos are a vital part of clinical trials as it is well documented that doing anything in medicine can cause a strong, temporary, physiological response in the body – the ‘placebo effect’. For an intervention to be considered effective it must show a significant effect over and above that seen in the placebo group. Blinding is when patients, doctors and assessors do not know whether the patient is taking medication or placebo. This means that the effects of the intervention, including side-effects, can be objectively identified. As a participant in a clinical trial it is important that you are aware that you may not received the active drug during the first stage of the trial.

Patients are randomly assigned to either the treatment or placebo group to avoid any bias in patient selection. People who wish to enrol in clinical trials must usually also meet certain requirements for a specific trial. This is to ensure that ‘apples are being compared with apples’. For example, an intervention may have different effects in people with relapsing-remitting MS compared to people with secondary progressive or primary progressive MS.

Depending on the intervention being trialled, the trial protocol may include some or all of these features, or additional design features.

When the results are put together from several clinical trials that all rigorously follow these international ‘gold-standard’ methods, there can be a high level of confidence that a new treatment is safe and effective.

Trial stages

Clinical trials are undertaken in carefully monitored and regulated phases:

Page2_ClinicalChart.jpg

Further reading

Detailed patient resources are available with further information on the clinical trials process and factors you may wish to take into consideration before participating in a clinical trial. We recommend the following:

Find a clinical trial

For a listing of MS clinical trials in Australia and New Zealand please [click here]